Wellgistics Health Inc. (WGRX) Financials
Newest figures come from the 10-Q for Q1 FY2026, filed May 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the WGRX SEC filings page.
Wellgistics Health Inc. (WGRX) reported $14.0M in revenue over the twelve months to Mar 31, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth masked collapsing unit economics, while external financing supported a shrinking balance sheet.
Revenue rose28.7% from FY2024 to FY2025, yet gross margin turned negative, indicating that growth did not preserve product-level economics. That shift coincided with operating margin falling to-401.7% and operating cash flow reaching-$10.9M , linking the reported loss to cash demands rather than an accounting-only decline.
Equity reversed sharply, moving from positive
The current ratio fell from 0.4x to 0.1x between FY2024 and FY2025, signaling a much tighter short-term funding position. In FY2025, financing inflow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Wellgistics Health Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Wellgistics Health Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 13/100.
Wellgistics Health Inc.'s revenue surged 28.7% year-over-year to $23.3M, reflecting rapid business expansion. This strong growth earns a score of 89/100.
Wellgistics Health Inc.'s current ratio of 0.09 is below the typical benchmark, resulting in a score of 1/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Not available for Wellgistics Health Inc., and counted as zero in the overall score.
Wellgistics Health Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Wellgistics Health Inc. reported a net loss of $101.3M while operations used $10.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Wellgistics Health Inc. reported an operating loss of $93.7M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Wellgistics Health Inc. generated $1.6M in revenue in Q1 2026. This represents a decrease of 85.6% from the same quarter a year earlier. Against the prior quarter it is down 6.6%.
Wellgistics Health Inc.'s EBITDA was -$5.7M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 81.5% from the same quarter a year earlier. Against the prior quarter it is up 76.9%.
Wellgistics Health Inc. reported -$7.7M in net income in Q1 2026. This represents an increase of 76.1% from the same quarter a year earlier. Against the prior quarter it is up 72.2%.
Cash & Balance Sheet
Wellgistics Health Inc. held $52K in cash against $12.6M in long-term debt as of Q1 2026.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
Wellgistics Health Inc.'s gross margin was 10.9% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is up 4.5 percentage points from the same quarter a year earlier.
Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q1 2026.
Capital Allocation
None of these metrics is reported for Q1 2026.
WGRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M-85.6% | $1.7M | $3.0M-46.9% | $7.8M+17391.8% | $10.9M | N/A | $5.7M | $45K |
| Cost of Revenue | $1.4M-86.3% | $9.5M | $2.8M-46.0% | $7.3M+15351.6% | $10.2M | N/A | $5.2M | $47K |
| Gross Profit | $170K-75.4% | -$7.9M | $231K-55.7% | $506K+19492.3% | $693K | N/A | $521K | -$3K |
| SG&A Expenses | $4.9M-84.4% | $4.1M | $30.2M+1577.5% | $4.9M+752.0% | $31.2M+38981.4% | N/A | $1.8M | $570K |
| Operating Income | -$6.0M+80.8% | -$25.4M | -$31.5M-1708.1% | -$5.5M-859.9% | -$31.3M-39201.4% | N/A | -$1.7M | -$573K |
| EBITDA | -$5.7M+81.5% | -$24.5M | -$30.7M-2306.9% | -$4.7M-719.8% | -$30.5M | N/A | -$1.3M | -$573K |
| Interest Expense | $2.1M+89.4% | $876K | $1.4M+935.7% | $1.2M+90353.8% | $1.1M+32493.5% | N/A | $138K | $1K |
| Net Income | -$7.7M+76.1% | -$27.9M | -$34.3M-1738.1% | -$6.7M-1061.8% | -$32.4M-38916.0% | N/A | -$1.9M | -$574K |
| EPS (Basic) | -$0.07+88.7% | N/A | -$0.46-1050.0% | -$0.11-1000.0% | -$0.62 | N/A | -$0.04 | -$0.01 |
| EPS (Diluted) | -$0.07 | N/A | -$0.46 | -$0.11-1000.0% | -$0.62 | N/A | -$0.04 | -$0.01 |
| Diluted Shares (Avg) | 105M | N/A | 74M | 62M+34.6% | 52M+16.1% | N/A | 48M | 46M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
WGRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $30.1M-48.1% | $30.5M-46.9% | $52.8M | $54.2M | $58.1M | $57.3M+16844.1% | N/A | N/A |
| Current Assets | $2.8M-83.3% | $2.8M-81.4% | $12.8M | $13.5M | $16.6M | $15.2M+4382.9% | N/A | N/A |
| Cash & Equivalents | $52K-97.9% | $43K-95.9% | $4.2M | $420K | $2.5M | $1.0M+75291.2% | N/A | N/A |
| Inventory | $1.7M-82.4% | $1.6M-82.8% | $7.5M | $9.0M | $9.7M | $9.5M | N/A | N/A |
| Accounts Receivable | $992K-64.9% | $1.1M-58.3% | $1.1M | $2.2M | $2.8M | $2.7M | N/A | N/A |
| Goodwill | $14.2M-12.5% | $14.2M-12.5% | $16.2M | $16.2M | $16.2M | $16.2M | N/A | N/A |
| Total Liabilities | $45.2M-15.7% | $42.9M-15.2% | $46.0M | $53.3M | $53.6M | $50.6M+1462.3% | N/A | N/A |
| Current Liabilities | $32.2M-30.3% | $29.8M-21.7% | $32.7M | $42.4M | $46.2M | $38.0M+1217.0% | N/A | N/A |
| Non-Current Liabilities | $13.0M+76.5% | $13.1M+4.6% | $13.3M | $10.9M | $7.4M | $12.6M+3486.1% | N/A | N/A |
| Long-Term Debt | $12.6M-47.8% | $12.6M+10.0% | $12.6M | $10.1M | $24.1M | $11.5M | N/A | N/A |
| Total Equity | -$15.1M-436.3% | -$12.4M-284.8% | $6.8M-32.1% | $905K+128.8% | $4.5M+250.1% | $6.7M+332.2% | $10.0M | -$3.1M |
| Retained Earnings | -$118.8M-181.5% | -$111.0M-1038.0% | -$83.2M | -$48.9M | -$42.2M | -$9.8M-236.3% | N/A | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
WGRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.4M-153.3% | -$6.3M-139.9% | -$1.1M-209.4% | -$2.1M-730.1% | -$1.3M-4413.6% | -$2.6M | $1.0M | $330K |
| Depreciation & Amortization | $357K-55.6% | $803K | $803K+71.7% | $803K | $803K | N/A | $467K | $0 |
| Stock-Based Compensation | $1.4M-95.1% | N/A | $25.7M | $935K | $27.8M | N/A | N/A | N/A |
| Investing Cash Flow | -$205K+24.9% | -$255K-131.8% | -$221K+30.0% | -$132K | -$273K | $803K | -$316K | N/A |
| Financing Cash Flow | $3.6M+16.7% | $2.4M+14.9% | $5.2M+114198.3% | $114K+121.2% | $3.1M+1095.7% | $2.1M | $5K | -$538K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
WGRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 10.9%+4.5pp | -470.2% | 7.7%-1.5pp | 6.5%+12.3pp | 6.4% | N/A | 9.2% | -5.9% |
| Operating Margin | -385.7% | -1517.5% | -1047.1% | -70.6% | -288.6% | N/A | -30.8% | -1286.5% |
| Net Margin | -496.5% | -1667.2% | -1139.0% | -85.6% | -298.5% | N/A | -32.9% | -1289.5% |
| Return on Equity | N/A | N/A | -506.3%-487.6pp | -737.1% | -724.1% | N/A | -18.7% | N/A |
| Return on Assets | -25.7%+30.1pp | -91.4% | -65.0% | -12.3% | -55.9% | N/A | N/A | N/A |
| Current Ratio | 0.09-0.3x | 0.09-0.3x | 0.39 | 0.32 | 0.36 | 0.40+0.3x | N/A | N/A |
| Debt-to-Equity | N/A | N/A | 1.86 | 11.16 | 5.39 | 1.70 | N/A | N/A |
| Asset Turnover | 0.05-0.1x | 0.05 | 0.06 | 0.14 | 0.19 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$12.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Wellgistics Health Inc. WGRX | FY2025 | $23.3M | -$101.3M | N/A | N/A | 25/100 |
| Petmed Express Inc PETS | FY2026 | $179.0M | -$57.3M | -32.0% | $36.9M | 26/100 |
| Scienture Holdings, Inc SCNX | FY2025 | $432K | -$41.5M | N/A | $14.7M | — |
| Cellyan Biotechnology Co Ltd HKPD | FY2025 | $20.3M | -$27K | -0.1% | $5.9M | 49/100 |
Where Wellgistics Health Inc. Ranks
Frequently Asked Questions
What is Wellgistics Health Inc.'s annual revenue?
Wellgistics Health Inc. (WGRX) reported $23.3M in total revenue for fiscal year 2025. This represents a 28.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Wellgistics Health Inc.'s revenue growing?
Wellgistics Health Inc. (WGRX) revenue grew by 28.7% year-over-year, from $18.1M to $23.3M in fiscal year 2025.
Is Wellgistics Health Inc. profitable?
No, Wellgistics Health Inc. (WGRX) reported a net income of -$101.3M in fiscal year 2025.
What is Wellgistics Health Inc.'s EBITDA?
Wellgistics Health Inc. (WGRX) had EBITDA of -$90.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Wellgistics Health Inc. have?
As of fiscal year 2025, Wellgistics Health Inc. (WGRX) had $43K in cash and equivalents against $12.6M in long-term debt.
What is Wellgistics Health Inc.'s gross margin?
Wellgistics Health Inc. (WGRX) had a gross margin of -27.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Wellgistics Health Inc.'s operating cash flow?
Wellgistics Health Inc. (WGRX) recorded an outflow of $10.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Wellgistics Health Inc.'s total assets?
Wellgistics Health Inc. (WGRX) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Wellgistics Health Inc.'s current ratio?
Wellgistics Health Inc. (WGRX) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Wellgistics Health Inc.'s return on assets (ROA)?
Wellgistics Health Inc. (WGRX) had a return on assets of -332.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Wellgistics Health Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Wellgistics Health Inc. (WGRX) held $43K in cash, cash equivalents and investments, and reported an operating cash outflow of $10.9M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Wellgistics Health Inc.'s debt-to-equity ratio negative or not reported?
Wellgistics Health Inc. (WGRX) has negative shareholder equity of -$12.4M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Wellgistics Health Inc.'s Piotroski F-Score?
Wellgistics Health Inc. (WGRX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Wellgistics Health Inc.'s earnings high quality?
Wellgistics Health Inc. (WGRX) reported a net loss of $101.3M while operations used $10.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Wellgistics Health Inc. cover its interest payments?
Wellgistics Health Inc. (WGRX) reported an operating loss of $93.7M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Wellgistics Health Inc.?
Wellgistics Health Inc. (WGRX) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.